Guggenheim Cuts argenx (ARGX) Price Target to $1,120
Key Points
- Guggenheim maintained a Buy rating on argenx SE and moved its price target down to $1,120.00 from $1,185.00 on October 23, 2026.
- Guggenheim's $1,120 price target implies 27.89% upside from argenx SE's ($ARGX) current $875.76 share price.
- The company's stock recently traded near $875.76, positioned below its average analyst consensus target.
- Several other Wall Street firms updated their views on the biotech firm on the same day.
Get argenx SE text alerts
We text you when insiders, Congress, analysts or big funds move on $ARGX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated argenx SE alert may contain errors. Disclosures
On October 23, 2026, Guggenheim maintained its Buy rating on argenx SE [ARGX] while adjusting its price target from $1,185.00 down to $1,120.00. The update arrived alongside several other fresh research notes from major financial institutions covering the biotechnology firm.
ARGX
argenx SE
Guggenheim vs. the S&P 500
Hypothetical returns from Guggenheim's disclosed trades, not real profit or advice. How we model this.
Guggenheim's Call on argenx SE
Guggenheim issued a research note on October 23, 2026, keeping a Buy rating on the stock while moving its target from $1,185.00 to $1,120.00. The adjustment places the firm's outlook in line with a broader group of Wall Street analysts evaluating the company's treatment portfolio and market position.
Other Institutional Activity in argenx SE
Jupiter Topco LLC grew its holdings by 1,237,008 shares, ending with 2,474,015 shares worth about $2,164,540,397.00. Artisan Partners Limited Partnership grew its holdings by 40,810 shares, ending with 1,508,778 shares worth about $1,320,044,919.00. Avoro Capital Advisors LLC kept its position steady with 1,000,000 shares valued at about $874,909,973.00. RTW Investments LP kept its stake unchanged at 709,446 shares worth roughly $620,701,380.00.
argenx SE Stock Down 1.6%
The stock recently traded around $875.76 as of October 23, 2026, sitting about equal to its closing price of $874.91 on the event date.
$ARGX price target
argenx SE daily closes and this analyst's $1,120 target. Not advice.
Recent Earnings
The company posted trailing twelve month revenue of $5.32 billion alongside an EPS of $28.87.
Analysts Set New Price Targets
On October 23, 2026, Morgan Stanley maintained its Overweight rating with a target of $1,190.00, up from $1,140.00. On October 23, 2026, Wells Fargo maintained its Overweight rating, lowering its target from $1,356.00 to $1,336.00. On October 23, 2026, Evercore ISI Group maintained an Outperform rating, raising its target from $1,078.00 to $1,090.00. On October 23, 2026, Baird maintained a Neutral rating, raising its target from $823.00 to $861.00. Overall, the stock holds a consensus buy recommendation across 23 analyst opinions with a mean price target of $1,150.91.
About argenx SE
argenx SE operates as a commercial-stage biopharmaceutical enterprise focused on creating immune-system treatments for severe autoimmune conditions. Its core commercial therapies target specific neurological and blood-related disorders, providing specialized care options in global markets. The firm continues to expand its clinical pipeline and commercial reach to address unmet medical needs in immunology.
Bottom Line
Investors will look to upcoming earnings reports and further institutional filings to track how argenx SE manages its ongoing drug development and market expansion. The recent series of analyst target adjustments reflects changing sentiment across Wall Street as the company progresses through its fiscal year.
Related Filing Alerts
Source: Guggenheim's rating change on $ARGX (Oct 23, 2026). Written by software, not financial advice. How we make alerts